291 related articles for article (PubMed ID: 34483946)
1. Distribution Evaluation of Tenofovir in the Breast Milk of Mothers With HBeAg-Positive Chronic HBV Infection After Treatment With Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate by a Sensitive UPLC-MS/MS Method.
Yang N; Zhou G; Cheng X; He J; Chen Y; Chen C; Li M; Ge J; Wang M; Zhang T; Ge W; Zhu H; Han G
Front Pharmacol; 2021; 12():734760. PubMed ID: 34483946
[TBL] [Abstract][Full Text] [Related]
2. Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection.
Kayes T; Crane H; Symonds A; Dumond J; Cottrell M; Di Girolamo J; Manandhar S; Lim TH; Gane E; Kashuba A; Levy MT
Aliment Pharmacol Ther; 2022 Aug; 56(3):510-518. PubMed ID: 35599363
[TBL] [Abstract][Full Text] [Related]
3. Low levels of tenofovir in breast milk support breastfeeding in HBV-infected mothers treated with tenofovir disoproxil fumarate.
Li S; Jin J; Jiang Y; Shi J; Jiang X; Lin N; Ma Z
Int J Antimicrob Agents; 2023 Mar; 61(3):106726. PubMed ID: 36646229
[TBL] [Abstract][Full Text] [Related]
4. Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamide-based ART.
Okochi H; Louie A; Phung N; Zhang K; Tallerico RM; Kuncze K; Spinelli MA; Koss CA; Benet LZ; Gandhi M
Drug Test Anal; 2021 Jul; 13(7):1354-1370. PubMed ID: 33742745
[TBL] [Abstract][Full Text] [Related]
5. Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide.
Lalley-Chareczko L; Hiserodt E; Moorthy G; Zuppa A; Mounzer K; Koenig H
Front Pharmacol; 2020; 11():286. PubMed ID: 32265700
[No Abstract] [Full Text] [Related]
6. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Agarwal K; Brunetto M; Seto WK; Lim YS; Fung S; Marcellin P; Ahn SH; Izumi N; Chuang WL; Bae H; Sharma M; Janssen HLA; Pan CQ; Çelen MK; Furusyo N; Shalimar D; Yoon KT; Trinh H; Flaherty JF; Gaggar A; Lau AH; Cathcart AL; Lin L; Bhardwaj N; Suri V; Mani Subramanian G; Gane EJ; Buti M; Chan HLY; ;
J Hepatol; 2018 Apr; 68(4):672-681. PubMed ID: 29756595
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load.
Li B; Liu Z; Liu X; Liu D; Duan M; Gu Y; Liu Q; Ma Q; Wei Y; Wang Y
Hepatol Int; 2021 Oct; 15(5):1103-1108. PubMed ID: 34312798
[TBL] [Abstract][Full Text] [Related]
8. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF).
De Clercq E
Biochem Pharmacol; 2016 Nov; 119():1-7. PubMed ID: 27133890
[TBL] [Abstract][Full Text] [Related]
9. Validation and implementation of liquid chromatographic-mass spectrometric (LC-MS) methods for the quantification of tenofovir prodrugs.
Hummert P; Parsons TL; Ensign LM; Hoang T; Marzinke MA
J Pharm Biomed Anal; 2018 Apr; 152():248-256. PubMed ID: 29433097
[TBL] [Abstract][Full Text] [Related]
10. Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40).
Imaz A; Niubó J; Cottrell ML; Perez E; Kashuba ADM; Tiraboschi JM; Morenilla S; Garcia B; Podzamczer D
Clin Infect Dis; 2019 Sep; 69(8):1403-1409. PubMed ID: 30561517
[TBL] [Abstract][Full Text] [Related]
11. Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy.
Ogawa E; Furusyo N; Nguyen MH
Drug Des Devel Ther; 2017; 11():3197-3204. PubMed ID: 29158666
[TBL] [Abstract][Full Text] [Related]
12. Effect of P-glycoprotein and Cotreatment with Sofosbuvir on the Intestinal Permeation of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Fumarate.
Huliciak M; Lhotska I; Kocova-Vlckova H; Halodova V; Dusek T; Cecka F; Staud F; Vokral I; Cerveny L
Pharm Res; 2023 Sep; 40(9):2109-2120. PubMed ID: 37594591
[TBL] [Abstract][Full Text] [Related]
13. An LC-MS/MS method for determination of tenofovir (TFV) in human plasma following tenofovir alafenamide (TAF) administration: Development, validation, cross-validation, and use of formic acid as plasma TFV stabilizer.
Xiao D; Ling KHJ; Tarnowski T; Majeed SR; German P; Kearney BP; Zhao Y; Chen YS; Ma L; Zhang T
Anal Biochem; 2020 Mar; 593():113611. PubMed ID: 32035040
[TBL] [Abstract][Full Text] [Related]
14. Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial.
Thurman AR; Schwartz JL; Cottrell ML; Brache V; Chen BA; Cochón L; Ju S; McGowan I; Rooney JF; McCallister S; Doncel GF
EClinicalMedicine; 2021 Jun; 36():100893. PubMed ID: 34041459
[TBL] [Abstract][Full Text] [Related]
15. Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate.
Kaneko S; Kurosaki M; Tamaki N; Itakura J; Hayashi T; Kirino S; Osawa L; Watakabe K; Okada M; Wang W; Shimizu T; Higuchi M; Takaura K; Yasui Y; Tsuchiya K; Nakanishi H; Takahashi Y; Watanabe M; Izumi N
J Gastroenterol Hepatol; 2019 Nov; 34(11):2004-2010. PubMed ID: 31017689
[TBL] [Abstract][Full Text] [Related]
16. Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
Podany AT; Bares SH; Havens J; Dyavar SR; O'Neill J; Lee S; Fletcher CV; Swindells S; Scarsi KK
AIDS; 2018 Mar; 32(6):761-765. PubMed ID: 29334548
[TBL] [Abstract][Full Text] [Related]
17. In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.
Callebaut C; Stepan G; Tian Y; Miller MD
Antimicrob Agents Chemother; 2015 Oct; 59(10):5909-16. PubMed ID: 26149992
[TBL] [Abstract][Full Text] [Related]
18. Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions?
Viganò M; Loglio A; Grossi G; Lampertico P
Expert Rev Anti Infect Ther; 2018 Feb; 16(2):153-161. PubMed ID: 29338458
[TBL] [Abstract][Full Text] [Related]
19. Tenofovir alafenamide (TAF) clinical pharmacology.
Di Perri G
Infez Med; 2021; 29(4):526-529. PubMed ID: 35146360
[TBL] [Abstract][Full Text] [Related]
20. Improved pharmacokinetics of tenofovir ester prodrugs strengthened the inhibition of HBV replication and the rebalance of hepatocellular metabolism in preclinical models.
Hong X; Cai Z; Zhou F; Jin X; Wang G; Ouyang B; Zhang J
Front Pharmacol; 2022; 13():932934. PubMed ID: 36105197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
